Hengrui Pharma Q1 2026 Results: Anti-PD-L1/TGF-βRII Fusion Protein Approved in China

Key Takeaways

• Hengrui Pharma secured approval for three innovative products including a novel anti-PD-L1/TGF-βRII bi-functional fusion protein in China during Q1 2026
• The company obtained 26 clinical trial approvals and 8 new drug application acceptances across oncology, metabolic, cardiovascular, and immunological diseases
• Revenue and net profit growth accompanied the regulatory milestones, strengthening Hengrui’s position in China’s pharmaceutical market

---

Hengrui Pharma Achieves Strong Q1 2026 Performance

Hengrui Pharma delivered robust financial results for the first quarter of 2026, reporting revenue and net profit growth alongside significant regulatory achievements in China’s pharmaceutical market.

The Chinese pharmaceutical giant secured approval for three innovative products during the quarter, headlined by a breakthrough anti-PD-L1/TGF-βRII bi-functional fusion protein. This novel oncology treatment represents a significant advancement in cancer immunotherapy, combining PD-L1 inhibition with TGF-β pathway modulation in a single therapeutic agent.

Expanding Treatment Options

Alongside the fusion protein approval, Hengrui obtained regulatory clearance for an indication expansion of its HER2-targeting antibody-drug conjugate (ADC). This approval broadens the treatment options available to patients with HER2-positive cancers, potentially extending the drug’s market reach and clinical utility.

Robust Pipeline Development

The company’s research and development momentum remained strong throughout Q1 2026, with 26 clinical trial approvals granted by Chinese regulators. These trials span multiple therapeutic areas including oncology, metabolic disorders, cardiovascular diseases, and immunological conditions, demonstrating Hengrui’s diversified drug development strategy.

Additionally, eight new drug applications received acceptance from regulatory authorities, moving these candidates closer to potential market approval. This pipeline advancement supports Hengrui’s long-term growth prospects and reinforces its position as a leading innovator in China’s pharmaceutical sector.

Market Implications

The combination of financial growth and regulatory success positions Hengrui Pharma favorably in the competitive Chinese pharmaceutical landscape. The anti-PD-L1/TGF-βRII fusion protein approval particularly strengthens the company’s oncology portfolio, addressing the growing demand for innovative cancer treatments in the Asia-Pacific region.

These developments reflect broader trends in China’s pharmaceutical market, where domestic companies are increasingly developing sophisticated biologics and targeted therapies to compete with international pharmaceutical giants.

---

Frequently Asked Questions

What makes the anti-PD-L1/TGF-βRII fusion protein innovative?

This bi-functional fusion protein combines two therapeutic mechanisms in one drug - PD-L1 inhibition for immune checkpoint blockade and TGF-β pathway modulation, potentially offering enhanced anti-tumor activity compared to single-target therapies.

When will these approved drugs be available to patients?

While specific launch timelines weren’t disclosed, approved drugs in China typically become available within 6-12 months following regulatory approval, pending manufacturing scale-up and distribution arrangements.

How does this compare to Hengrui’s previous quarterly performance?

The Q1 2026 results show continued growth in both revenue and net profit, with the three drug approvals representing a significant regulatory milestone that exceeds typical quarterly approval numbers for the company.